Lenisna (PDLLA + HA Hybrid)
PDLLA + HA hybrid biostimulator for liquid thread lift effect
이 치료에 대해
Lenisna is a hybrid biostimulator from Regen Biotech (Korea) containing 170mg PDLLA (poly-D,L-lactic acid) + 30mg non-crosslinked hyaluronic acid. With approximately 4x more PDLLA than standard Juvelook (42.5mg), it achieves a gentle "liquid thread lift" effect.
PDLLA microspheres (50-60μm) act as dermal scaffolding to activate fibroblasts and promote type I & III neocollagenesis. HA provides immediate hydration and helps distribute PDLLA evenly, delivering natural results from the moment of injection.
작용 기전
PDLLA microspheres (50-60μm) activate surrounding fibroblasts via TGF-β1 pathway, promoting type I collagen production. PDLLA hydrolyzes over 12-24 months into lactic acid. Non-crosslinked HA is absorbed within 48-72 hours, providing initial hydration and injection uniformity.
적응증
기대 효과
Immediate hydration effect from HA. Collagen-driven lifting peaks at 1-3 months. Duration 12-24 months. 4x PDLLA content provides more pronounced lifting than standard Juvelook.
임상 근거
위험 및 부작용
Injection site swelling/redness (2-5 days). Rare nodule formation (especially with overcorrection in thin skin). PDLLA is non-reversible. Technique-dependent results require experienced injectors.